GBR 600

Drug Profile

GBR 600

Alternative Names: CHR-1201; GRC 600

Latest Information Update: 10 Jun 2014

Price : $50

At a glance

  • Originator Chromos Molecular Systems
  • Developer Glenmark Pharmaceuticals S.A.
  • Class Antiplatelets; Antithrombotics; Monoclonal antibodies
  • Mechanism of Action Von Willebrand factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Acute coronary syndromes; Stroke; Thrombosis

Most Recent Events

  • 25 May 2011 Preclinical trials in Acute coronary syndromes (adjunctive threapy) in USA (Parenteral)
  • 24 Jul 2007 Glenmark Pharmaceuticals acquires CHR 1201 from Chromos Molecular Systems
  • 09 Feb 2005 Preclinical trials in Stroke in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top